Shreedhar Nagnur, MD
Internal Medicine · Newnan, GANPI 1538168968
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (58.0%), food and beverage and speaking fees — rather than concentrated in one kind of arrangement. 11 manufacturers reported payments, led by AstraZeneca at 58.6% of the total. Reporting peaked in 2020 at $1,940 and has fallen 93.4% since, to $129 in 2025.
Across 33 payments — averaging $78.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Ortho Dermatologics, A Division Of Bausch Health US, LLC$440
- Mallinckrodt Hospital Products Inc.$129
- Novartis$126
- Pfizer$87
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$86
- plus $204 from 5 others
What the payments were for
- Consulting fees$1,50058%
- Speaking & faculty fees$44017%
- Food & beverage$64825%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 2 | $1,515 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 1 | $440 |
| Mallinckrodt Hospital Products Inc. | 1 | $129 |
| Novartis | 7 | $126 |
| Pfizer | 5 | $87 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $86 |
| Merck | 4 | $65 |
| Johnson & Johnson | 4 | $53 |
| AbbVie(2 entities) | 3 | $47 |
| Otsuka America Pharmaceutical, Inc. | 1 | $20 |
| Shire North American Group Inc | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,588 in reported general payments places this provider in the 80th percentile of 3,311 internal medicine providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Atorvastatin Calcium | 17 | $213 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 24 | $212 |
| Famotidine | 12 | $181 |
| Metoprolol Succinate | 18 | $172 |
| Cefdinir | 11 | $123 |
| Hydralazine Hcl | 14 | $109 |
| Furosemide | 16 | $99 |
| Prednisone | 22 | $54 |
| Metoprolol Tartrate | 12 | $29 |
| Amlodipine Besylate | 11 | $21 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Newnan
- Michael GibsonSmyrna$2.2M
- Eduard FatakhovAlpharetta$376K
- Tracey HenryAtlanta$305K
- Sharon TuckettVilla Rica$265K
- Ebon BourneMarietta$242K
- Jennifer WoehlerSavannah$207K
- Julian HutchinsGreensboro$201K
- Brian PearlmanDalton$199K
- Scott ParryAtlanta$162K
- Jennifer GilliganAtlanta$162K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.